| 000 | 01684 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514195900.0 | ||
| 264 | 0 | _c20041108 | |
| 008 | 200411s 0 0 eng d | ||
| 022 | _a0362-5664 | ||
| 024 | 7 |
_a10.1097/01.wnf.0000135478.70905.3d _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHill, Michael P | |
| 245 | 0 | 0 |
_aLevetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. _h[electronic resource] |
| 260 |
_bClinical neuropharmacology _c |
||
| 300 |
_a171-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnticonvulsants _xtherapeutic use |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCallithrix |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aDyskinesias _xdrug therapy |
| 650 | 0 | 4 | _aLevetiracetam |
| 650 | 0 | 4 |
_aLevodopa _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aMPTP Poisoning _xdrug therapy |
| 650 | 0 | 4 |
_aPiracetam _xanalogs & derivatives |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aBrotchie, Jonathan M | |
| 700 | 1 | _aCrossman, Alan R | |
| 700 | 1 | _aBezard, Erwan | |
| 700 | 1 | _aMichel, Anne | |
| 700 | 1 | _aGrimée, Renee | |
| 700 | 1 | _aKlitgaard, Henrik | |
| 773 | 0 |
_tClinical neuropharmacology _gvol. 27 _gno. 4 _gp. 171-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.wnf.0000135478.70905.3d _zAvailable from publisher's website |
| 999 |
_c15018320 _d15018320 |
||